Table 1 |
||
|
Clinical characteristics of all patients at baseline and follow-up |
||
|
Baseline |
Follow-up |
|
|
|
||
|
Creatinine, μmol/L |
92.3 (46.6) |
81.6 (42.6) |
|
Proteinuria, g/day |
2.0 (1.8) |
0.7 (0.8) |
|
C3, g/L |
0.53 (0.23) |
0.80 (0.23) |
|
C4, g/L |
0.09 (0.06) |
0.13 (0.07) |
|
C1q |
66.6% (41.0%) |
75.2% (29.5%) |
|
Anti-dsDNA-positivea |
83% |
44% |
|
Glomerular filtration rate |
80.7 (29.4) |
88.6 (26.4) |
|
U-erythrocytes > 1+ |
79% |
46% |
|
Renal histology, number |
||
|
Class I |
15 |
1 |
|
Class II |
12 |
13 |
|
Class III |
2 |
6 |
|
Class IV |
6 |
3 |
|
Class III/V |
12 |
|
|
Class V |
||
|
Activity index |
5.7 (3.1) |
2.5 (2.3) |
|
Chronicity index |
1.8 (2.0) |
2.3 (2.3) |
|
Treatment, number |
||
|
Cyclophosphamide |
21 |
|
|
Mycophenolate mofetil |
8 |
|
|
Rituximab |
5 |
|
|
Azathioprin |
1 |
|
|
BILAG renal index, number |
||
|
A |
32 |
2 |
|
B |
3 |
18 |
|
C |
7 |
|
|
D |
8 |
|
|
|
||
|
Values are presented as mean (standard deviation) unless otherwise indicated. aAnti-double-stranded DNA (anti-dsDNA) raised to at least 1:25. BILAG, British Isles lupus assessment group. |
||
|
Zickert et al. Arthritis Research & Therapy 2012 14:R36 doi:10.1186/ar3747 |
||
